Table 3. Multiple Treatment Comparison for Tolerability Based on Network Consistency Model.
| Comparison | OR (95% CI)a | |||||||
|---|---|---|---|---|---|---|---|---|
| TRAE 3-5 | Leukopenia | Neutropenia | Anemia | Thrombocytopenia | Diarrhea | Vomiting | Nausea | |
| Etoposide plus cisplatin/carboplatinb | ||||||||
| Etoposide plus cisplatin/carboplatin plus bevacizumab | 0.64 (0.29-1.35) | 1.10 (0.14-8.83) | 1.12 (0.34-3.98) | NA | 0.51 (0.11-2.20) | 0.00 (0.00-0.37) | 0.63 (0.06-5.54) | 0.14 (0.01-1.82) |
| Etoposide plus cisplatin/carboplatin plus ipilimumab | 0.87 (0.36-2.31) | 2.52 (0.33-20.51) | 1.84 (0.37-9.61) | 1.38 (0.42-4.81) | 1.19 (0.26-5.44) | 0.07 (0.00-11.32) | 0.60 (0.04-4.90) | 0.37 (0.05-2.37) |
| Etoposide plus cisplatin/carboplatin plus PD-L1 | 1.14 (0.56-2.21) | 0.92 (0.12-7.12) | 1.32 (0.39-4.36) | 1.29 (0.53-3.14) | 1.16 (0.39-3.47) | 0.43 (0.01-18.66) | 2.42 (0.32-29.55) | 3.50 (0.56-31.74) |
| Irinotecan plus cisplatin/carboplatin | 2.71 (1.04-7.00) | 1.81 (0.64-4.91) | 3.73 (1.92-7.24) | 1.35 (0.83-2.19) | 2.58 (1.53-4.56) | 0.07 (0.01-0.32) | 0.50 (0.18-1.13) | 0.57 (0.28-1.07) |
| Etoposide plus cisplatin/carboplatin plus bevacizumabc | ||||||||
| Etoposide plus cisplatin/carboplatin plus ipilimumab | 1.36 (0.44-4.72) | 2.37 (0.12-44.51) | 1.63 (0.20-11.85) | NA | 2.36 (0.29-19.73) | 1.47 × 108 (0.09-9.23 × 1032) | 0.92 (0.04-23.56) | 2.59 (0.10-115.96) |
| Etoposide plus cisplatin/carboplatin plus PD-L1 | 1.76 (0.63-5.01) | 0.86 (0.05-16.98) | 1.16 (0.20-6.38) | NA | 2.29 (0.36-13.86) | 8.27 × 108 (0.90-5.60 × 1033) | 4.00 (0.19-116.21) | 27.37 (1.03-1123.70) |
| Irinotecan plus cisplatin/carboplatin | 4.24 (1.26-14.57) | 1.69 (0.16-15.89) | 3.29 (0.80-13.53) | NA | 5.11 (1.09-24.81) | 1.21 × 108 (0.13-5.74 × 1032) | 0.79 (0.07-9.69) | 3.91 (0.30-106.06) |
| Etoposide plus cisplatin/carboplatin plus ipilimumabc | ||||||||
| Etoposide plus cisplatin/carboplatin plus PD-L1 | 1.29 (0.39-4.05) | 0.36 (0.02-6.52) | 0.72 (0.09-5.31) | 0.93 (0.21-4.11) | 0.97 (0.15-6.06) | 5.89 (0.01-3050.86) | 4.15 (0.25-111.54) | 10.07 (0.60-159.51) |
| Irinotecan plus cisplatin/carboplatin | 3.09 (0.81-11.14) | 0.71 (0.07-6.94) | 2.00 (0.36-12.28) | 0.97 (0.26-3.54) | 2.17 (0.45-11.35) | 0.96 (0.00-128.02) | 0.83 (0.08-13.85) | 1.54 (0.20-12.18) |
| Etoposide plus cisplatin/carboplatin plus PD-L1c | ||||||||
| Irinotecan plus cisplatin/carboplatin | 2.37 (0.74-7.93) | 1.94 (0.19-18.69) | 2.81 (0.72-10.94) | 1.05 (0.38-2.88) | 2.23 (0.68-7.81) | 0.16 (0.00-7.94) | 0.20 (0.01-1.75) | 0.16 (0.02-1.13) |
Abbreviations: NA, not applicable; OR, odds ratio; PD-L1, programmed cell death ligand 1; TRAE 3-5, treatment-related adverse event, grades 3 to 5.
a
An OR greater than 1 indicates that the treatment in the row heading was associated with lower likelihood of adverse events than the treatment it is being compared with.
b
All comparisons with etoposide plus cisplatin/carboplatin were direct.
c
All comparisons with etoposide plus cisplatin/carboplatin and bevacizumab, etoposide plus cisplatin/carboplatin and ipilimumab, etoposide plus cisplatin/carboplatin with PD-L1, and irinotecan plus cisplatin/carboplatin are indirect.